187 related articles for article (PubMed ID: 6978147)
21. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.
Seto S; Carrera CJ; Kubota M; Wasson DB; Carson DA
J Clin Invest; 1985 Feb; 75(2):377-83. PubMed ID: 2579098
[TBL] [Abstract][Full Text] [Related]
22. The effect of deoxycoformycin and deoxyadenosine on deoxyribonucleotide concentrations in leukaemic cells.
Sylwestrowicz T; Piga A; Murphy P; Ganeshaguru K; Russell NH; Prentice HG; Hoffbrand AV
Br J Haematol; 1982 Aug; 51(4):623-30. PubMed ID: 6980665
[TBL] [Abstract][Full Text] [Related]
23. Alterations in erythrocyte adenine nucleotide pools resulting from 2'-deoxycoformycin therapy.
Koller CA; Mitchell BS
Cancer Res; 1983 Mar; 43(3):1409-14. PubMed ID: 6600652
[TBL] [Abstract][Full Text] [Related]
24. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
[TBL] [Abstract][Full Text] [Related]
25. Inhibitor of 2',5'-oligoadenylate synthetase induced in human T lymphoblastoid cell line treated with deoxyadenosine, deoxycoformycin and interferon.
Heike T; Katamura K; Kubota M; Shinomiya K; Mikawa H
Biochem Biophys Res Commun; 1985 Mar; 127(3):1019-25. PubMed ID: 3872657
[TBL] [Abstract][Full Text] [Related]
26. Energy metabolism in adenosine deaminase-inhibited human erythrocytes.
Buc HA; Thuillier L; Hamet M; Garreau F; Moncion A; Pérignon JL
Clin Chim Acta; 1986 Apr; 156(1):61-9. PubMed ID: 3486057
[TBL] [Abstract][Full Text] [Related]
27. Deoxyribonucleoside triphosphate accumulation by leukemic cells.
Mitchell BS; Edwards NL; Koller CA
Blood; 1983 Aug; 62(2):419-24. PubMed ID: 6603241
[TBL] [Abstract][Full Text] [Related]
28. Successful remission induction with deoxycoformycin in elderly patients with T-helper prolymphocytic leukaemia.
el'Agnaf MR; Ennis KE; Morris TC; Robertson JH; Markey G; Alexander HD
Br J Haematol; 1986 May; 63(1):93-104. PubMed ID: 2939873
[TBL] [Abstract][Full Text] [Related]
29. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
[TBL] [Abstract][Full Text] [Related]
30. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
[TBL] [Abstract][Full Text] [Related]
31. Biochemical correlates of the differential sensitivity of subtypes of human leukemia to deoxyadenosine and deoxycoformycin.
Matsumoto SS; Yu AL; Bleeker LC; Bakay B; Kung FH; Nyhan WL
Blood; 1982 Nov; 60(5):1096-102. PubMed ID: 6289941
[TBL] [Abstract][Full Text] [Related]
32. Differential sensitivity of leukemic cells to growth inhibition by deoxyadenosine and deoxycoformycin.
Tanaka M; Kimura K
Tohoku J Exp Med; 1985 Dec; 147(4):331-41. PubMed ID: 3879563
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo effect of deoxycoformycin in human T cell leukemia.
Yu AL; Kung FH; Bakay B; Nyhan WL
Adv Exp Med Biol; 1979; 122B():373-9. PubMed ID: 397762
[No Abstract] [Full Text] [Related]
34. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.
Prentice HG; Russell NH; Lee N; Ganeshaguru K; Blacklock H; Piga A; Smyth JF; Hoffbrand AV
Lancet; 1981 Dec; 2(8258):1250-4. PubMed ID: 6118669
[TBL] [Abstract][Full Text] [Related]
35. Determinants of deoxyadenosine toxicity in hybrids between human T- and B- lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia.
Kurtzberg J; Hershfield MS
Cancer Res; 1985 Apr; 45(4):1579-86. PubMed ID: 3872167
[TBL] [Abstract][Full Text] [Related]
36. T-cell chronic lymphocytic leukaemia: anomalous cell markers, variable morphology, and marked responsiveness to pentostatin (2'-deoxycoformycin).
Spiers AS; Davis MP; Levine M; Li CY; Mangan KF; Mazza JJ; Neu LT; O'Brien J; Rauch AE; Wiltsie JC
Scand J Haematol; 1985 Jan; 34(1):57-67. PubMed ID: 2578689
[TBL] [Abstract][Full Text] [Related]
37. Treatment of cutaneous T cell lymphoma with 2'-deoxycoformycin (pentostatin).
Dang-Vu AP; Olsen EA; Vollmer RT; Greenberg ML; Hershfield MS
J Am Acad Dermatol; 1988 Oct; 19(4):692-8. PubMed ID: 3263401
[TBL] [Abstract][Full Text] [Related]
38. Role of glycolysis in deoxyadenosine induced ATP depletion and dATP accumulation in red cells.
Koller CA; Orringer EP; Berkowitz LR; Mulhern AT
Prog Clin Biol Res; 1984; 165():227-39. PubMed ID: 6334314
[No Abstract] [Full Text] [Related]
39. Inhibition of adenosine deaminase activity results in cytotoxicity to T lymphoblasts in vivo.
Mitchell BS; Koller CA; Heyn R
Blood; 1980 Sep; 56(3):556-9. PubMed ID: 6967747
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes.
Bontemps F; Van den Berghe G
Cancer Res; 1989 Sep; 49(18):4983-9. PubMed ID: 2788493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
